Sign In
Buy PRTK
$2.23
+0 (+0%)
At Close: Dec 19, 2023
BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of no
NEW YORK , Aug. 22, 2023 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Paratek Pharmaceuticals, Inc. ("Paratek" or the "C
STAMFORD, Conn.--(BUSINESS WIRE)--Abbott Cooper PLLC announces that it is investigating Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) (“Paratek” or the “Company”) on behalf of the Company's inv
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
10:31am, Thursday, 03'rd Aug 2023
Paratek Pharmaceuticals (PRTK) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.33 per share a year ago.
Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million
08:00am, Thursday, 03'rd Aug 2023
-- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022
Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 per Share on Achievem
NEW YORK , July 12, 2023 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Paratek Pharmaceuticals, Inc. (" Paratek" or the
Plans to Investigate All Records to Ensure Board Did Not Breach Fiduciary Duty DALLAS , July 11, 2023 /PRNewswire/ -- NexPoint Event Driven Fund today issued a demand letter to the Board of Directors
-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement expected in early 2024
7 Growth Stocks That Are Too Cheap to Ignore Right Now
03:31pm, Wednesday, 10'th May 2023
Although the equities sector recovered reasonably well from 2022's harsh glare, rising headwinds force consideration of cheap growth stocks to buy now. Essentially, some enterprises with upside potent
Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9
08:30am, Monday, 01'st May 2023
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m.
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
04:47pm, Friday, 31'st Mar 2023 Benzinga
Gainers
Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter.
Inpixon (NASDAQ: INPX) jumped 37.9% to $0.5101. Inpixon reported a 21%
$1.6M Bet On ATAI Life Sciences? Check Out These 4 Penny Stocks Insiders Are Buying
11:15am, Thursday, 30'th Mar 2023 Benzinga
The Dow Jones closed higher by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders
Why Titan Machinery Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
05:56pm, Thursday, 16'th Mar 2023 Benzinga
Gainers
Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) shares jumped 40.2% to $2.5109 after the company announced the successful completion of a Phase 2A clinical trial evaluating the safety and efficac
Paratek Pharmaceuticals, Inc. (PRTK) Q4 2022 Earnings Call Transcript
02:14pm, Thursday, 16'th Mar 2023
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Sarah Higgins - VP, Finance, and Principal Accounting Officer Evan Loh - CE
